No abstract

Nanomedicine and plasma medicine are innovative and multidisciplinary research fields aiming to employ nanotechnology and gas plasma to improve health-related treatments. Especially cancer treatment has been in the focus of both approaches because clinical response rates with traditional methods that remain improvable for many types of tumor entities. Here, we discuss the recent progress of nanotechnology and gas plasma independently as well as in the concomitant modality of nanoplasma as multimodal platforms with unique capabilities for addressing various therapeutic issues in oncological research. The main features, delivery vehicles, and nexus between reactivity and therapeutic outcomes of nanoparticles and the processes, efficacy, and mechanisms of gas plasma are examined. Especially that the unique feature of gas plasma technology, the local and temporally controlled deposition of a plethora of reactive oxygen, and nitrogen species released simultaneously might be a suitable additive treatment to the use of systemic nanotechnology therapy approaches. Finally, we focus on the convergence of plasma and nanotechnology to provide a suitable strategy that may lead to the required therapeutic outcomes.

Cold atmospheric pressure plasma (CAP) is emerging as new healthcare technology and it has a high potential through physical and chemical effects for cancer treatment. Recently, CAP, plasma activated liquid (PAL), and nanomaterial have been significant advances in oncotherapy. Reactive oxygen-nitrogen species (RONS), electrical field, and other agents generated by CAP interact with cells and induce selective responses between the malignant and normal cells. Nanomedicine enhances therapeutic effectiveness and decreases the side effects of traditional treatments due to their target delivery and dispersion in tumor tissue. There are various nanocarriers (NCs) which based on their properties can be used for the delivery of different agents. The combination of gas plasma and nanomaterials technologies is a new multimodal treatment in cancer treatment, therefore, is expected that the conjunction of these technologies addresses many of the oncology challenges. This chapter provides a framework for current research of NC and gas plasma therapies for lung cancer. Herein, we focus on the application of gas plasmas and nanotechnology to drug and gene delivery and highlight several outcomes of its. The types and features of the mentioned therapeutics strategy as novel classes for treating lung cancer individually and synergistic were examined.

Background: Primordial follicle includes an oocyte surrounded by a layer of somatic cells called Granulosa Cells (GCs). GCs, also known as nurse cells, are an important protective element for the growth and survival of oocytes. Oocytes, which lack some of the metabolic processes, require granulosa cells for their development. Objectives: This manuscript was provided to explain the protocol of GCs primary culture extracted from NMRI mice ovaries. Methods: For choosing the optimum protocol, we used two methods with different culture mediums to obtain more GCs and expedite the process. Hematoxylin and Eosin (H&E) staining and flow cytometry were used to analyze the type of extracted cells from ovaries. Besides, we evaluated the effect of crocin and DPP as two common natural products in Iran on the proliferation of these cells via MTT assay. Results: Second protocol method and alpha-MEM culture medium were chosen based on the results. Our findings from HE staining and flow cytometry proved the percentage of cultured GCs in the flask. Further, MTT assessment demonstrated that crocin at high doses had a toxic effect on granulosa cells, whereas date palm pollen (DPP) stimulated them to proliferation. Conclusion: Modifying this protocol is for the improvement of proliferation, coherence, and quality of GCs in primary culture and subculture. Regarding the effect of these two natural products on granulosa cells, we can mention the bilateral effect of crocin and DPP enhancement in proliferation.